PMID- 35818701
OWN - NLM
STAT- MEDLINE
DCOM- 20220713
LR  - 20221207
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 37
IP  - 27
DP  - 2022 Jul 11
TI  - Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective 
      Cohort Study.
PG  - e210
LID - 10.3346/jkms.2022.37.e210 [doi]
LID - e210
AB  - BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there 
      are concerns regarding waning immunity and the emergence of viral variants. The 
      immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe 
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. 
      METHOD: This prospective cohort study was conducted between June 2021 and January 
      2022 at two university hospitals in South Korea. Healthy adults who were 
      scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main 
      outcomes included anti-spike (S) IgG antibody and neutralizing antibody 
      responses, S-specific T-cell responses (interferon-gamma enzyme-linked immunospot 
      assay), solicited adverse events (AEs), and serious AEs. RESULTS: Fifty 
      participants aged >/= 19 years were included in the study. Geometric mean titers 
      (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 +/- 3.0 U/mL at 3-4 weeks, 55.7 
      +/- 2.4 U/mL at 5-8 weeks, and 81.3 +/- 2.5 U/mL at 10-12 weeks after vaccination. 
      GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 +/- 4.6 
      at 3-4 weeks, 313.9 +/- 3.6 at 5-8 weeks, and 124.4 +/- 2.6 at 10-12 weeks after 
      vaccination. As for the S-specific T-cell responses, the median number of 
      spot-forming units/10(6) peripheral blood mononuclear cell was 25.0 (5.0-29.2) at 
      baseline, 60.0 (23.3-178.3) at 5-8 weeks, and 35.0 (13.3-71.7) at 10-12 weeks 
      after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron 
      variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent 
      AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and 
      fever (50%). Most AEs were grade 1-2, and resolved within two days. CONCLUSION: 
      Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell 
      immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. 
      Cross-reactive neutralizing activity against the Omicron variant was negligible.
CI  - (c) 2022 The Korean Academy of Medical Sciences.
FAU - Hyun, Hakjun
AU  - Hyun H
AUID- ORCID: 0000-0002-1193-8948
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
FAU - Choi, Min Joo
AU  - Choi MJ
AUID- ORCID: 0000-0002-2739-0948
AD  - Department of Internal Medicine, International St. Mary's Hospital, Catholic 
      Kwandong University College of Medicine, Incheon, Korea.
FAU - Heo, Jung Yeon
AU  - Heo JY
AUID- ORCID: 0000-0002-6548-1939
AD  - Department of Infectious Diseases, Ajou University School of Medicine, Suwon, 
      Korea.
FAU - Seo, Yu Bin
AU  - Seo YB
AUID- ORCID: 0000-0001-5183-1996
AD  - Division of Infectious Diseases, Department of Internal Medicine, Kangnam Sacred 
      Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
FAU - Nham, Eliel
AU  - Nham E
AUID- ORCID: 0000-0001-7509-4863
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
FAU - Yoon, Jin Gu
AU  - Yoon JG
AUID- ORCID: 0000-0003-3283-1880
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
FAU - Seong, Hye
AU  - Seong H
AUID- ORCID: 0000-0002-5633-7214
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
FAU - Noh, Ji Yun
AU  - Noh JY
AUID- ORCID: 0000-0001-8541-5704
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
AD  - Asia Pacific Influenza Institute, Korea University College of Medicine, Seoul, 
      Korea.
AD  - Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.
FAU - Cheong, Hee Jin
AU  - Cheong HJ
AUID- ORCID: 0000-0002-2532-1463
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
FAU - Kim, Woo Joo
AU  - Kim WJ
AUID- ORCID: 0000-0002-4546-3880
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
AD  - Asia Pacific Influenza Institute, Korea University College of Medicine, Seoul, 
      Korea.
AD  - Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.
FAU - Choi, Ju-Yeon
AU  - Choi JY
AUID- ORCID: 0000-0003-3477-8569
AD  - Division of Vaccine Clinical Research, Center for Vaccine Research, National 
      Institute of Infectious Diseases, Cheongju, Korea.
FAU - Lee, Young Jae
AU  - Lee YJ
AUID- ORCID: 0000-0002-4902-2281
AD  - Division of Vaccine Clinical Research, Center for Vaccine Research, National 
      Institute of Infectious Diseases, Cheongju, Korea.
FAU - Lee, Hye Won
AU  - Lee HW
AUID- ORCID: 0000-0001-8391-1165
AD  - Division of Vaccine Clinical Research, Center for Vaccine Research, National 
      Institute of Infectious Diseases, Cheongju, Korea.
FAU - Kim, Sung Soon
AU  - Kim SS
AUID- ORCID: 0000-0003-2774-6710
AD  - Division of Vaccine Clinical Research, Center for Vaccine Research, National 
      Institute of Infectious Diseases, Cheongju, Korea.
FAU - Kim, Byoungguk
AU  - Kim B
AUID- ORCID: 0000-0001-9084-4490
AD  - Division of Vaccine Clinical Research, Center for Vaccine Research, National 
      Institute of Infectious Diseases, Cheongju, Korea. kimbg10@korea.kr.
FAU - Song, Joon Young
AU  - Song JY
AUID- ORCID: 0000-0002-0148-7194
AD  - Division of Infectious Diseases, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
AD  - Asia Pacific Influenza Institute, Korea University College of Medicine, Seoul, 
      Korea.
AD  - Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea. 
      infection@korea.ac.kr.
LA  - eng
GR  - 2021-ER2603-01/Korea Disease Control and Prevention Agency/Korea
PT  - Journal Article
DEP - 20220711
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - JT2NS6183B (Ad26COVS1)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - Ad26COVS1
MH  - Adult
MH  - Antibodies, Neutralizing
MH  - Antibodies, Viral
MH  - *COVID-19
MH  - Humans
MH  - Leukocytes, Mononuclear
MH  - Prospective Studies
MH  - *SARS-CoV-2
PMC - PMC9274104
OTO - NOTNLM
OT  - Adenovirus Vector
OT  - Adverse Events
OT  - COVID-19
OT  - Cellular Immunity
OT  - Humoral Immunity
OT  - SARS-CoV-2
OT  - Vaccines
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2022/07/13 06:00
MHDA- 2022/07/14 06:00
PMCR- 2022/07/11
CRDT- 2022/07/12 02:44
PHST- 2022/04/29 00:00 [received]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/07/12 02:44 [entrez]
PHST- 2022/07/13 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/07/11 00:00 [pmc-release]
AID - 37.e210 [pii]
AID - 10.3346/jkms.2022.37.e210 [doi]
PST - epublish
SO  - J Korean Med Sci. 2022 Jul 11;37(27):e210. doi: 10.3346/jkms.2022.37.e210.